Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

The first kidney stone

Article Abstract:

A review of the medical literature on the treatment of kidney stones suggests that drug treatment may not be appropriate for calcium-based kidney stones. Other forms of stones, such as the uric acid stones which occur in gout, are not considered in this review. When a patient is treated for his first kidney stone, the first question to be raised is how to prevent recurrence. The drugs available for prevention of calcium-based kidney stones, allopurinol and the thiazides, are not completely effective and are not without side effects. Allopurinol can cause rashes and liver deterioration; the thiazides mildly increase the level of fats in the blood. Examination of the statistics shows that treating 100 patients with thiazides for five years will probably save only seven from surgery, while five patients will experience significant side effects. Careful evaluation of clinical laboratory values in conjunction with dietary control may be more appropriate. (Consumer Summary produced by Reliance Medical Information, Inc.)

Author: Uribarri, Jaime, Oh, Man S., Carroll, Hugh J.
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1989
Complications and side effects, Kidney stones, Thiazides, Allopurinol

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Every kidney counts

Article Abstract:

Strategies need to be developed to improve the success rate for kidney transplants. The number of kidneys available for transplantation is considerably less than number of the patients waiting for an organ. A research study found that a kidney transplant is more likely to be successful when all six of the HLA antigens of the transplant donor and the transplant recipient are matched. Another research study found that poor compliance with follow-up treatment is a major factor contributing to the failure of kidney transplants. Transplant recipients must be treated with immunosuppressant drugs to prevent rejection of the transplanted organ. Younger patients and those from a lower socioeconomic background have a higher risk of poor compliance than other patients. Some of these patients do not have enough money to purchase immunosuppressant drugs. Providing funding for immunosuppressant drugs may improve the kidney transplant success rate.

Author: Braun, William E.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1992
Prevention, Graft rejection, Kidneys, Kidney transplantation

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Judges from the Stone Age

Article Abstract:

A man who murdered his unfaithful wife received a sentence of only 18 months in a detention center, and another judge merely fined a rapist who assaulted an unconscious woman. Biased judges must be held accountable by the public.

Publisher: Conde Nast Publications, Inc.
Publication Name: Glamour
Subject: Health
ISSN: 0017-0747
Year: 1995
Evaluation, Judges, Judicial process

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Editorial
Similar abstracts:
  • Abstracts: Enterovirus deja vu. Cochlear implants. Fertilizing or contaminating?
  • Abstracts: An abundance of options. Boning up on estrogen: new options, new concerns. Can-do curtain options
  • Abstracts: So that young hearts may thrive.... Women sports stars: a new set of role models. Big stars, big hearts
  • Abstracts: Sex, romance, and the new dad. Fresh-squeezed fun. A newsworthy mom
  • Abstracts: Comment: The Democracy of Facts. Comment: Federal Statistical Coordination. Mobile phone radiation - the facts
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.